JP2012514004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012514004A5 JP2012514004A5 JP2011543705A JP2011543705A JP2012514004A5 JP 2012514004 A5 JP2012514004 A5 JP 2012514004A5 JP 2011543705 A JP2011543705 A JP 2011543705A JP 2011543705 A JP2011543705 A JP 2011543705A JP 2012514004 A5 JP2012514004 A5 JP 2012514004A5
- Authority
- JP
- Japan
- Prior art keywords
- topical composition
- positively charged
- integer
- kojic acid
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 84
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 claims description 81
- 229960004705 kojic acid Drugs 0.000 claims description 74
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 claims description 74
- 230000000699 topical effect Effects 0.000 claims description 39
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 32
- 108010039918 Polylysine Proteins 0.000 claims description 20
- 229920000656 polylysine Polymers 0.000 claims description 20
- 208000012641 Pigmentation disease Diseases 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 11
- 239000000049 pigment Substances 0.000 claims description 9
- 206010042496 Sunburn Diseases 0.000 claims description 8
- -1 penetrant Substances 0.000 claims description 8
- 230000037317 transdermal delivery Effects 0.000 claims description 8
- 229920002873 Polyethylenimine Polymers 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 239000003349 gelling agent Substances 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 239000003981 vehicle Substances 0.000 claims description 6
- 108700031308 Antennapedia Homeodomain Proteins 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000000975 dye Substances 0.000 claims description 5
- 230000003061 melanogenesis Effects 0.000 claims description 5
- 230000019612 pigmentation Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000004909 Moisturizer Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000007844 bleaching agent Substances 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 230000001333 moisturizer Effects 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 3
- 230000002087 whitening effect Effects 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 239000006096 absorbing agent Substances 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000010445 mica Substances 0.000 claims description 2
- 229910052618 mica group Inorganic materials 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims 2
- 108010011110 polyarginine Proteins 0.000 claims 2
- 229920002704 polyhistidine Polymers 0.000 claims 2
- 229920002714 polyornithine Polymers 0.000 claims 2
- 108010055896 polyornithine Proteins 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003581 cosmetic carrier Substances 0.000 claims 1
- 239000000419 plant extract Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- KANINNSSRWMGIP-UHFFFAOYSA-M sodium;butyl 4-hydroxybenzoate;dodecyl sulfate;hexadecan-1-ol;methyl 4-hydroxybenzoate;octadecan-1-ol;propane-1,2-diol;propyl 4-hydroxybenzoate Chemical compound [Na+].CC(O)CO.COC(=O)C1=CC=C(O)C=C1.CCCOC(=O)C1=CC=C(O)C=C1.CCCCOC(=O)C1=CC=C(O)C=C1.CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCO KANINNSSRWMGIP-UHFFFAOYSA-M 0.000 claims 1
- 239000004563 wettable powder Substances 0.000 claims 1
- 239000007854 depigmenting agent Substances 0.000 description 36
- 210000003491 skin Anatomy 0.000 description 36
- 239000000243 solution Substances 0.000 description 20
- 238000009472 formulation Methods 0.000 description 15
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 14
- 102000003425 Tyrosinase Human genes 0.000 description 14
- 108060008724 Tyrosinase Proteins 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
- 230000004907 flux Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 208000000069 hyperpigmentation Diseases 0.000 description 8
- 230000003810 hyperpigmentation Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000003367 kinetic assay Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 6
- 229960004441 tyrosine Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 108010043958 Peptoids Proteins 0.000 description 4
- 206010040829 Skin discolouration Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002845 discoloration Methods 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920000333 poly(propyleneimine) Polymers 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000037370 skin discoloration Effects 0.000 description 3
- 210000004870 skin-related structure Anatomy 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 125000001151 peptidyl group Chemical group 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 108010064470 polyaspartate Proteins 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- ODAYPJXLKLHBFQ-UHFFFAOYSA-N (5-hydroxy-4-oxopyran-2-yl)methyl 2-hydroxybenzoate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC(=O)C(O)=CO1 ODAYPJXLKLHBFQ-UHFFFAOYSA-N 0.000 description 1
- MYDWRIZWCBNFJY-UHFFFAOYSA-N (5-hydroxy-4-oxopyran-2-yl)methyl 3,4-dihydroxybenzoate Chemical compound C1=C(O)C(O)=CC=C1C(=O)OCC1=CC(=O)C(O)=CO1 MYDWRIZWCBNFJY-UHFFFAOYSA-N 0.000 description 1
- UCKGHBXASBGMPD-UHFFFAOYSA-N (5-hydroxy-4-oxopyran-2-yl)methyl 3-hydroxybenzoate Chemical compound OC1=CC=CC(C(=O)OCC=2OC=C(O)C(=O)C=2)=C1 UCKGHBXASBGMPD-UHFFFAOYSA-N 0.000 description 1
- JLYOMEVXVQXCCQ-UHFFFAOYSA-N (5-hydroxy-4-oxopyran-2-yl)methyl 4-hydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OCC1=CC(=O)C(O)=CO1 JLYOMEVXVQXCCQ-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- AMLFJZRZIOZGPW-NSCUHMNNSA-N (e)-prop-1-en-1-amine Chemical compound C\C=C\N AMLFJZRZIOZGPW-NSCUHMNNSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XESZUVZBAMCAEJ-UHFFFAOYSA-N 4-tert-butylcatechol Chemical compound CC(C)(C)C1=CC=C(O)C(O)=C1 XESZUVZBAMCAEJ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- GPKMZACUUQFPGH-UHFFFAOYSA-N C=NS(=O)=O Chemical compound C=NS(=O)=O GPKMZACUUQFPGH-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical group CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000213810 Ephelis Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AUVATLMXOAEIQQ-UHFFFAOYSA-N OC1=C(C(=O)OCC=2OC=C(CC2)O)C=CC=C1O Chemical compound OC1=C(C(=O)OCC=2OC=C(CC2)O)C=CC=C1O AUVATLMXOAEIQQ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 125000000909 amidinium group Chemical group 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- 125000005496 phosphonium group Chemical group 0.000 description 1
- 229910052698 phosphorus Chemical group 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium group Chemical group [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14209408P | 2008-12-31 | 2008-12-31 | |
| US61/142,094 | 2008-12-31 | ||
| PCT/US2009/069578 WO2010078244A1 (en) | 2008-12-31 | 2009-12-28 | Compositions and methods for treating hyperpigmentation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012514004A JP2012514004A (ja) | 2012-06-21 |
| JP2012514004A5 true JP2012514004A5 (https=) | 2014-11-13 |
| JP5836128B2 JP5836128B2 (ja) | 2015-12-24 |
Family
ID=42285228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011543705A Expired - Fee Related JP5836128B2 (ja) | 2008-12-31 | 2009-12-28 | 色素過剰を治療するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20120014894A1 (https=) |
| EP (1) | EP2379177A1 (https=) |
| JP (1) | JP5836128B2 (https=) |
| KR (1) | KR20110112381A (https=) |
| CN (1) | CN102292126B (https=) |
| RU (1) | RU2011125776A (https=) |
| SG (1) | SG172811A1 (https=) |
| WO (1) | WO2010078244A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2558676C (en) | 2004-03-03 | 2019-04-16 | Essentia Biosystems, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| SG160357A1 (en) * | 2005-03-03 | 2010-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| CN104857514B (zh) * | 2015-05-15 | 2018-01-19 | 东华大学 | 一种胰岛素脂质体透皮促进剂及其制备方法 |
| KR102607534B1 (ko) * | 2015-12-28 | 2023-11-29 | 오비다트 주식회사 | TATdMt 펩타이드를 포함하는 미백 조성물 |
| KR102304280B1 (ko) | 2018-08-14 | 2021-09-23 | 올리패스 주식회사 | 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드 |
| KR102206808B1 (ko) * | 2019-09-05 | 2021-01-26 | 주식회사 에스스킨 | 신규한 세포-투과 펩타이드 및 이를 포함하는 피부 개선용 조성물 |
| WO2021056106A1 (en) | 2019-09-23 | 2021-04-01 | Dds Research Inc. | Lipid vesicle compositions with penetration enhancing agents |
| MX2023011157A (es) * | 2021-03-24 | 2024-01-25 | Glo Pharma Inc | Peptidos y metodos para reducir la pigmentacion de la piel. |
| KR102598095B1 (ko) * | 2022-08-31 | 2023-11-07 | 주식회사 레메디 | 피부 미백 활성을 가지는 펩타이드를 포함하는 조성물 |
| WO2025072381A1 (en) * | 2023-09-25 | 2025-04-03 | Revance Therapeutics, Inc. | Methods for determining influence of carrier peptide on the binding of a therapeutic protein to a cell membrane |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6483010A (en) * | 1987-09-25 | 1989-03-28 | Sansho Seiyaku Kk | Melanization inhibitory drug for external use |
| US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
| US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
| US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| US20040043463A1 (en) * | 2002-09-03 | 2004-03-04 | Pingfan Rao | Peptide-tagged proteins and compositions for regulating features of the skin or hair; methods of making, and methods of using thereof |
| US20070154437A1 (en) * | 2002-09-03 | 2007-07-05 | Pingfan Rao | Peptide-tagged proteins and methods of making and using thereof |
| CN1946431B (zh) * | 2004-03-03 | 2011-12-07 | 雷文斯治疗公司 | 用于肉毒毒素的局部施用和透皮递送的组合物和方法 |
-
2009
- 2009-12-28 CN CN200980155232.1A patent/CN102292126B/zh not_active Expired - Fee Related
- 2009-12-28 US US13/141,962 patent/US20120014894A1/en not_active Abandoned
- 2009-12-28 EP EP09837074A patent/EP2379177A1/en not_active Withdrawn
- 2009-12-28 US US12/647,739 patent/US20100166689A1/en not_active Abandoned
- 2009-12-28 WO PCT/US2009/069578 patent/WO2010078244A1/en not_active Ceased
- 2009-12-28 KR KR1020117017755A patent/KR20110112381A/ko not_active Ceased
- 2009-12-28 RU RU2011125776/15A patent/RU2011125776A/ru not_active Application Discontinuation
- 2009-12-28 SG SG2011047891A patent/SG172811A1/en unknown
- 2009-12-28 JP JP2011543705A patent/JP5836128B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5836128B2 (ja) | 色素過剰を治療するための組成物及び方法 | |
| JP2012514004A5 (https=) | ||
| CN109998938B (zh) | 一种用于美白亮肤淡斑的多肽组合物 | |
| CN103096980B (zh) | 皮肤抗衰老治疗 | |
| CA2859419C (en) | Cosmetic composition comprising an aqueous extract of navy-bean | |
| KR20140024877A (ko) | 식물 추출물을 포함하는 국소 스킨 케어 제형 | |
| TW200817039A (en) | Compositions and methods for skin lightening | |
| EA023699B1 (ru) | Композиция для местного нанесения на кожу | |
| JP4088436B2 (ja) | 皮膚外用剤 | |
| CA3042740A1 (en) | Putrescine slow-release topical formulations | |
| CA3118491A1 (en) | Crosslinked materials | |
| JP2000212082A (ja) | 皮膚用剤 | |
| JP2017511346A (ja) | 皮膚を水和させるための美容組成物 | |
| CN117731544B (zh) | 一种含杏仁酸的具有靶向透皮递送功能的淡斑淡印美白增效组合物、其制备方法及其应用 | |
| JP5455292B2 (ja) | 皮膚外用組成物 | |
| JP2004131401A (ja) | 皮膚化粧料 | |
| JP2004182635A (ja) | 皮膚外用剤 | |
| WO2023009502A1 (en) | Anti-aging cosmetic compositions comprising xanthommatin | |
| WO2006059798A1 (ja) | 経皮吸収促進用油性皮膚外用組成物 | |
| JP2004182636A (ja) | 皮膚外用剤 | |
| JP2021038217A (ja) | 皮膚外用組成物、抗炎症成分又は抗菌成分の皮膚浸透性をコントロールする方法、及び抗炎症成分又は抗菌成分による皮膚刺激を低減する方法 | |
| HK1165741B (en) | Compositions and methods for treating hyperpigmentation | |
| JPH01121205A (ja) | 美白化粧料 | |
| HK1165741A (en) | Compositions and methods for treating hyperpigmentation | |
| JP5659407B2 (ja) | 経皮吸収促進性皮膚外用剤 |